iGlarLixi effectively reduces residual hyperglycaemia in patients with type 2 diabetes on basal insulin: A post hoc analysis from the LixiLan-L study.

Morea N, Retnakaran R, Vidal J, Aroda VR, Liu M, Saremi A, Giorgino F

Diabetes, obesity & metabolism28 May 2020Cited by 12 (Europe PMC)

PMID32363634PMCIDPMC7497103DOI10.1111/dom.14077PepBankPUB-32363634

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, residual hyperglycaemia affected 23.8% with iGlarLixi versus 47.1% with glargine after 30 weeks (P < .0001).
In plain wordsIn patients with type 2 diabetes, adding lixisenatide to glargine reduced residual high blood sugar versus glargine.
Peptide
Lixisenatide
Outcome
DecreaseResidual hyperglycaemia at week 30
Study
n = 736
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 30 weeksAs given in this study (human).
Measurements
Patients with residual hyperglycaemia
23.8%
iGlarLixi, after 30 weeks
Patients with residual hyperglycaemia
47.1%
iGlar, after 30 weeks
P
< 0.0001
between groups
Source sentences
Summary
After 30 weeks, the proportion of patients with residual hyperglycaemia declined to 23.8% in the iGlarLixi versus 47.1% in the iGlar arm (P < .0001).
2 context sentences(design, population, supporting numbers)
Summary · context
Following the run-in period, 736 patients were then randomized to receive iGlarLixi or were continued on iGlar for 30 weeks ± metformin.
Summary · context
Residual hyperglycaemia was defined as HbA1c ≥ 7.0% despite FPG of <140 mg/dL.
Report a problemFND-3236363401
02HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, combined HbA1c and FPG target attainment was 50.3% with iGlarLixi versus 27.4% with glargine (P < .0001).
In plain wordsIn patients with type 2 diabetes, adding lixisenatide to glargine increased combined HbA1c and fasting glucose target attainment versus glargine.
Peptide
Lixisenatide
Outcome
IncreaseCombined HbA1c and FPG target attainment
Study
n = 736
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 30 weeksAs given in this study (human).
Measurements
Patients achieving HbA1c <7.0% and FPG <140 mg/dL
50.3%
iGlarLixi, after 30 weeks
Patients achieving HbA1c <7.0% and FPG <140 mg/dL
27.4%
iGlar, after 30 weeks
P
< 0.0001
between groups
Source sentences
Summary
The proportion of patients achieving both HbA1c (<7.0%) and FPG (<140 mg/dL) targets was higher in the iGlarLixi compared with the iGlar arm (50.3% vs. 27.4%, respectively; P < .0001).
2 context sentences(design, population, supporting numbers)
Summary · context
Following the run-in period, 736 patients were then randomized to receive iGlarLixi or were continued on iGlar for 30 weeks ± metformin.
Summary · context
Residual hyperglycaemia was defined as HbA1c ≥ 7.0% despite FPG of <140 mg/dL.
Report a problemFND-3236363402

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.